The growth of molecular quality controls market is
primarily driven by factors such as the rising adoption of third-party quality
controls, increasing number of accredited clinical laboratories, the rising
demand for external quality assessment support, increasing government funding
to support genomics projects, increasing demand for personalized medicines and
declining costs of sequencing procedures and increasing prevalence of
infectious diseases, cancer & genetic diseases.
The molecular quality controls market size is expected to grow from USD 164 million in 2021 to USD 226 million by 2026, at a CAGR of 6.7% during the forecast period.
The prominent players in the molecular quality
controls market are F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories,
Inc. (US), Thermo Fisher Scientific, Inc. (US), Randox Laboratories Ltd. (UK),
LGC Limited (UK), Abbott Laboratories (US), Fortress Diagnostics (UK), SERO AS
(Norway), Anchor Molecular (US), Ortho-Clinical Diagnostics, Inc. (US), Quidel
Corporation (US), Sun Diagnostics, Seegene Inc. (South Korea), ZeptoMetrix, LLC
(US), Qnostics (UK), Bio-Techne Corporation (US), Microbiologics, Inc. (US),
Microbix Biosystems Inc. (Canada), SpeeDx Pty. Ltd. (Australia), Maine
Molecular Quality Controls, Inc. (US), and Grifols, S.A. (Spain).
LGC Limited (UK) held
the leading position in the molecular quality controls market. The company
provides a wide range of quality controls and reference materials under its
flagship brands ACCURUN and Seraseq. The company also offers customer support
services, technical support, and training for its diagnostic kits to various
end users. SeraCare provides assurance in test results for oncology,
non-invasive prenatal testing, and infectious disease identification with its
advanced quality control technology. The company is focusing on organic
strategies such as product launches to maintain and increase its share in the
market. In the past three years, SeraCare launched 19 new molecular quality
control materials under its brand name Seraseq and AccuPlex. In June 2021, LGC
SeraCare expanded its line of SARS-CoV-2 molecular quality solutions to include
AccuPlex SARS-CoV-2 Variant Panel 1. These product launches helped the company
in strengthening its presence in the molecular quality controls market.
Thermo Fisher Scientific, Inc. held the second position in the global molecular quality controls
market. The company is a leading provider of molecular quality control
products. The company offers a robust portfolio of quality controls for clinical
chemistry, molecular control, microbiology, serology, serum toxicology testing,
specimen validity testing, and therapeutic drug monitoring (TDM). With its
strong geographic presence and wide distribution networks, the company has
established itself as a leader in the global molecular quality controls market.
To sustain its leading position and further increase its share in the market,
the company focuses on organic and inorganic growth strategies. Thermo Fisher
assisted with the pandemic response by quickly developing the Applied
Biosystems TaqPath COVID-19 Combo Kit. This kit was granted emergency use
authorization in the US in March 2020, followed by similar authorizations
worldwide. The company launched the Thermo Fisher Scientific COVID-19 product
line, which greatly increased its inventory of COVID-19-related items. The
company invested USD 1.20 billion in R&D to deliver newer technologies by
creating reliable and innovative products.
Request Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523
Bio-Rad Laboratories held the third position in the molecular quality controls market.
The company supplies more than 3,000 products covering more than 300 clinical
diagnostic tests. It has a wide range of product offerings for the Life Science
and Clinical Diagnostics segments. To maintain its leading position in this
market, the company has adopted inorganic growth strategies such as
partnerships and acquisitions. The company focuses on inorganic growth
strategies to diversify its product portfolio. For instance, in May 2021,
Bio-Rad entered a global partnership with Roche Diagnostics (Switzerland) to
provide their customers access to Bio-Rad’s complete line of InteliQ products
and Unity QC data management solutions along with customer training and support
services. Similarly, in February 2020, the company acquired Exact Diagnostics
(US) to access a comprehensive catalog of molecular quality control products in
transplant, respiratory, virology, microbiology, sexually transmitted
infections, and vector-borne diseases.